Mental Health Screening Before GLP-1 Prescribing: Why Good Providers Ask About Mood

The conversation about GLP-1 medications and mental health has evolved rapidly since 2023. What started with isolated reports of mood changes in patients taking semaglutide has expanded into a broader clinical discussion about the psychological dimensions of rapid weight loss, the importance of pre-treatment mental health screening, and what comprehensive GLP-1 care should look like.

Why Mental Health Screening Matters

Mental health screening before GLP-1 prescribing serves multiple purposes, and none of them are about gatekeeping treatment. The goals are clinical safety, realistic expectation-setting, and ensuring patients have appropriate support structures in place.

Baseline documentation: If a patient experiences mood changes during GLP-1 treatment, having a documented baseline allows the clinical team to distinguish medication-related effects from pre-existing conditions or life circumstances.

Identifying high-risk patients: Patients with active eating disorders (particularly binge eating disorder or bulimia), untreated depression, anxiety disorders, or a history of suicidal ideation deserve extra clinical attention — not to deny them treatment, but to ensure appropriate co-management with mental health professionals.

Anticipatory guidance: Rapid weight loss affects identity, relationships, body image, and social dynamics in ways that many patients don't anticipate. Providers who screen for mental health can offer proactive guidance about these transitions.

The FDA Review: Suicidal Ideation and GLP-1s

In early 2025, the FDA conducted a formal safety review after reports of suicidal ideation and self-harm in patients taking GLP-1 medications. The review examined data from clinical trials, post-marketing surveillance, and real-world evidence databases.

The FDA's conclusion was that the available evidence did not establish a causal link between GLP-1 medications and suicidal behavior. However, the agency noted that continued monitoring was warranted and recommended that providers screen for mood disorders and suicidal ideation at baseline and periodically during treatment.

It's important to contextualize these reports. Obesity itself is associated with higher rates of depression and anxiety. Weight loss — from any cause — can trigger complex emotional responses. And the sheer number of patients now taking GLP-1 medications (tens of millions globally) means that adverse mental health events will occur by statistical probability alone, even without a causal medication effect.

What Good Screening Looks Like

A quality pre-GLP-1 mental health screening should cover the following areas, either through validated questionnaires or structured clinical interview:

• Current mood state — the PHQ-9 (Patient Health Questionnaire) is a widely used, validated 9-item depression screening tool. A score of 10 or above suggests moderate depression warranting further evaluation.
• Anxiety symptoms — the GAD-7 (Generalized Anxiety Disorder scale) provides a quick, standardized anxiety assessment.
• Eating disorder screening — specific questions about binge eating, purging behaviors, food restriction, and relationship with food. The SCOFF questionnaire is a brief validated screen.
• Suicidal ideation — direct, compassionate questioning about suicidal thoughts, plans, or history. This is a clinical standard, not an overreaction.
• Body image and weight history — understanding the patient's emotional relationship with their body and weight helps predict how they'll respond to rapid physical changes.
• Social support assessment — patients with strong social networks tend to navigate the psychological aspects of weight loss more successfully.

The Psychological Dimensions of GLP-1 Weight Loss

Even patients with no pre-existing mental health conditions may experience unexpected emotional responses to rapid weight loss. Understanding these responses as normal and predictable helps patients navigate them more effectively:

Identity disruption: For patients who have been in a larger body for years or decades, rapid weight change can trigger an identity crisis. How others perceive you changes, how you perceive yourself changes, and the social dynamics of your relationships shift — sometimes dramatically.

Grief for former coping mechanisms: Many patients used food as an emotional coping strategy. When GLP-1 medications reduce the drive to eat, the coping mechanism disappears before a replacement is established. This can feel like loss.

Relationship changes: Partners, friends, and family members may respond to your weight loss in unexpected ways — some supportive, some uncomfortable, some undermining. These dynamics can be emotionally challenging.

The "now what?" plateau: When patients reach their weight loss goal and the initial excitement fades, a sense of emptiness or purposelessness can emerge. Weight loss was the project; now what replaces it?

Attention and comments from others: Unwanted comments about appearance — even positive ones — can feel invasive and reduce the patient's sense of autonomy over their own body and health decisions.